Leo Pharma chairman: "In the long term, we will probably have fewer employees"

The pharmaceutical company's ownership circle, including Nordic Capital, is accelerating the transformation of Leo Pharma, and according to Chairman of the Board Jesper Brandgaard this could mean fewer employees in the long term.

Photo: Leo Pharma.

Leo Pharma's transformation is moving up a gear, and according to Chairman of the Board Jesper Brandgaard, this could have consequences for the company's staff, which today counts 5,800 people, reports Danish business daily Børsen.

"What the count will be, time will tell. We don't have a specific target we have to reach. In the long term, we will probably have fewer employees," Brandgaard tells Børsen.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs